A confirmatory Phase 3 trial of apraglutide for patients with short bowel syndrome (SBS) with intestinal failure (IF) who are dependent on parenteral support
Latest Information Update: 20 Apr 2025
At a glance
- Drugs Apraglutide (Primary)
- Indications Intestinal failure; Short bowel syndrome
- Focus Pharmacokinetics; Registrational
- Sponsors Ironwood Pharmaceuticals
Most Recent Events
- 20 Apr 2025 New trial record
- 14 Apr 2025 According to an Ironwood Pharmaceuticals media release, the company announced that, based on a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial is needed to seek approval. The company plans to work with the FDA on the design of a confirmatory Phase 3 trial and the regulatory path forward.